
    
      This is A multi-center, randomized, double-blind, parallel controlled Phase III clinical
      trial.

      The primary objective is to evaluate the clinical efficacy of MW032 and Xgeva® in patients
      with bone metastases from solid tumors.

      The secondary objective are to evaluate the clinical safety and immunogenicity of MW032 and
      Xgeva® in patients with bone metastases from solid tumors.
    
  